Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis-Reference-Cited by-同舟云学术

Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis

Published:2024-04-13 Issue:3 Volume:19 Page:371-382
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Basso Michele^ORCID,Signorelli Carlo,Calegari Maria Alessandra,Lucchetti Jessica,Zurlo Ina Valeria,Dell’Aquila Emanuela,Arrivi Giulia,Zoratto Federica,Santamaria Fiorenza,Saltarelli Rosa,Trovato Giovanni,Caira Giulia,Angotti Lorenzo,Schirripa Marta,Anghelone Annunziato,Schietroma Francesco,Chilelli Mario Giovanni,Salvatore Lisa,Pozzo Carmelo,Tortora Giampaolo

Funder

Università Cattolica del Sacro Cuore

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11523-024-01050-3.pdf

Reference23 articles.

1. Benson AIB, Venook AP, Al-Hawary MM, et al. NCCN clinical practice guidelines in oncology: colon cancer, version 2.2021. J Natl Compr Canc Netw. 2021;19:329–59.

2. Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39:273–84.

3. Overman MJ, McDermott R, Leach JJ, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91.

4. André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–18.

5. Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022;23(1):115–24. https://doi.org/10.1016/S1470-2045(21)00605-7.